Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Bio-Techne is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-23Current report (material event)
- DEFA14A2026-09-14DEFA14A
- 8-K2026-09-14Current report (material event)
- DEFA14A2026-09-09DEFA14A
- DEFA14A2026-09-02DEFA14A
- DEFA14A2026-08-25DEFA14A
- 10-K2026-08-24Annual report
- DEFM14A2026-08-20DEFM14A
- 8-K2026-08-12Current report (material event)
- PREM14A2026-08-10PREM14A
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- DEFA14A2026-07-09DEFA14A
- 8-K2026-06-26Current report (material event)
- DEFA14A2026-06-25DEFA14A
- 8-K2026-06-25Current report (material event)
- SD2026-06-01SD
- 10-Q2026-05-06Quarterly report
- SCHEDULE 13G2026-05-06SCHEDULE 13G
- 8-K2026-05-06Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 8-K2026-02-11Current report (material event)
- 10-Q2026-02-04Quarterly report
- 8-K2026-02-04Current report (material event)
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- 10-Q2025-11-05Quarterly report
- 8-K2025-11-05Current report (material event)
- ARS2025-09-19Annual report to holders
- DEFA14A2025-09-19DEFA14A
- DEF 14A2025-09-19Proxy statement
- 10-K2025-08-22Annual report
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- 8-K2025-08-06Current report (material event)
- SCHEDULE 13G/A2025-07-16SCHEDULE 13G/A
- SD2025-05-30SD
- SCHEDULE 13G/A2025-05-14SCHEDULE 13G/A
- 10-Q2025-05-08Quarterly report
- 8-K2025-05-07Current report (material event)
- 8-K2025-05-06Current report (material event)
- 8-K2025-03-04Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.